Star Bulk Carriers Corp vs Smith & Nephew plc — how do they compare? Star Bulk Carriers Corp trades at $26.63 (market cap $2.91B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 4.3× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.95%). Which is the better fit depends on your goals.
| SBLK | SNN | |
|---|---|---|
Market Cap | $2.91B | $12.64B |
Sector | Industrials | Health |
52-Week High | $28.21 | $38.70 |
52-Week Low | $16.79 | $28.73 |
Enterprise Value | $3.61B | $15.41B |
Dividend Yield | 3.95% | 2.57% |
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $26.09, up 4.78% in the last session. Technical indicators are bearish, but fundamentals show strength with a P/E of 19.92 and net income margin of 13.01%. Recent earnings beat expectations in Q4 2025 and Q1 2026, with Q2 2026 EPS expected at $0.96. The company maintains a healthy balance sheet and pays dividends, including a recent $0.50 per share distribution.
Outlook is cautiously optimistic due to strong dry bulk rates and fleet modernization driving cash flow. Risks include shipping rate volatility and macroeconomic pressures. Analyst consensus is bullish with 58.34% buy ratings, but technical weakness suggests near-term caution. The stock offers value with a 10%+ dividend yield potential if rates sustain.
No Aura AI signal available yet.
Trailing returns across standard periods
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →